Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Pawelec

Showing results (151-160 of 173) with videos related to

Pageof 18
Sort By:
Clinical Reviews in Allergy & Immunology|September 18, 2021
Immunology of Aging: the Birth of InflammagingT Fulop, A Larbi, G Pawelec, et al.
Blut|March 1, 1987
HLA-class II antigens on human hematopoietic progenitorsF W Busch, M Langer, G Pawelec, et al.
Molecular Biotherapy|March 1, 1990
Lymphokine release, suppressor cell generation, cell surface markers, and cytotoxic activity in cancer patients receiving natural interleukin-2G Pawelec, U Schwuléra, H Lenz, et al.
Cellular Immunology|April 15, 1995
Human gamma delta T cells are resistant to induction of anergy but not to induction of cell death in vitroG Pawelec, H Friccius, M Boshell, et al.
Leukemia|April 22, 2006
A novel MHC-associated proteinase 3 peptide isolated from primary chronic myeloid leukaemia cells further supports the significance of this antigen for the immunotherapy of myeloid leukaemiasA J Knights, A O Weinzierl, T Flad, et al.
Critical Reviews in Oncogenesis|May 18, 1999
Cells and cytokines in immunotherapy and gene therapy of cancerG Pawelec, R C Rees, R Kiessling, et al.
Transplant Immunology|December 1, 1994
Role of three quantitatively dominant endogenous peptides from HLA-DRB1*0401 molecules in class II specific alloreactivityM Adibzadeh, H Friccius, S Bornhak, et al.
Tissue Antigens|February 1, 1988
HLA-DP in rheumatoid arthritisG Pawelec, P Reekers, D Brackertz, et al.
Leukemia & Lymphoma|August 1, 1995
Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alphaG Pawelec, P Da Silva, H Max, et al.
Experimental Gerontology|March 31, 2004
Validation of a new highly standardised, lab-independent whole-blood leukocyte function assay for clinical trials (ILCS)M Schmolz, T L Hurst, D M Bailey, et al.
Pageof 18

Showing results (151-160 of 173) with videos related to

Sort By:
Pageof 18
Clinical Reviews in Allergy & Immunology|September 18, 2021
Immunology of Aging: the Birth of InflammagingT Fulop, A Larbi, G Pawelec, et al.
Blut|March 1, 1987
HLA-class II antigens on human hematopoietic progenitorsF W Busch, M Langer, G Pawelec, et al.
Molecular Biotherapy|March 1, 1990
Lymphokine release, suppressor cell generation, cell surface markers, and cytotoxic activity in cancer patients receiving natural interleukin-2G Pawelec, U Schwuléra, H Lenz, et al.
Cellular Immunology|April 15, 1995
Human gamma delta T cells are resistant to induction of anergy but not to induction of cell death in vitroG Pawelec, H Friccius, M Boshell, et al.
Leukemia|April 22, 2006
A novel MHC-associated proteinase 3 peptide isolated from primary chronic myeloid leukaemia cells further supports the significance of this antigen for the immunotherapy of myeloid leukaemiasA J Knights, A O Weinzierl, T Flad, et al.
Critical Reviews in Oncogenesis|May 18, 1999
Cells and cytokines in immunotherapy and gene therapy of cancerG Pawelec, R C Rees, R Kiessling, et al.
Transplant Immunology|December 1, 1994
Role of three quantitatively dominant endogenous peptides from HLA-DRB1*0401 molecules in class II specific alloreactivityM Adibzadeh, H Friccius, S Bornhak, et al.
Tissue Antigens|February 1, 1988
HLA-DP in rheumatoid arthritisG Pawelec, P Reekers, D Brackertz, et al.
Leukemia & Lymphoma|August 1, 1995
Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alphaG Pawelec, P Da Silva, H Max, et al.
Experimental Gerontology|March 31, 2004
Validation of a new highly standardised, lab-independent whole-blood leukocyte function assay for clinical trials (ILCS)M Schmolz, T L Hurst, D M Bailey, et al.
Pageof 18